Gonadorelin (GnRH): the complete guide.

Gonadorelin is the synthetic decapeptide identical to endogenous GnRH (gonadotropin-releasing hormone) — the hypothalamic signal that runs the entire reproductive axis. Studies have examined its use across pulsatile fertility induction, diagnostic pituitary-function testing, and, more recently, as an off-label TRT-adjunct alternative to HCG. The HPG-axis biology is well-characterized. The TRT-adjunct evidence base is thin.

Scope of this monograph

This article covers gonadorelin's molecular identity, HPG-axis pharmacology, clinical history (Factrel and Lutrepulse), and the published evidence base for its studied indications — hypothalamic hypogonadotropic hypogonadism, diagnostic pituitary-function testing, and ovulation induction. It also reviews the TRT-adjunct off-label use as examined in the literature, including the evidence gaps.

The central finding the evidence supports: no head-to-head RCT has compared gonadorelin to HCG for testicular preservation in testosterone-replacement contexts.

What is gonadorelin?

Gonadorelin is a lab-made copy of GnRH (gonadotropin-releasing hormone), sometimes also called LHRH (luteinizing hormone-releasing hormone). The two names describe the same molecule.

The sequence is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. That's 10 amino acids, with a special blocked group on each end. The sequence matches native human GnRH at every position. Gonadorelin isn't a modified analog. It's the real thing, made in a peptide synthesizer.

Two researchers, Andrew Schally and Roger Guillemin, isolated and sequenced GnRH in the early 1970s. They shared the 1977 Nobel Prize in Physiology or Medicine for the work. We've been able to make gonadorelin synthetically ever since.

Where it sits in the body

GnRH sits at the top of the HPG axis (the hypothalamus-pituitary-gonadal hormone loop). The hypothalamus releases GnRH in tiny pulses. Those pulses hit the pituitary, which then releases LH and FSH. LH and FSH travel to the testes or ovaries and drive testosterone, estrogen, sperm, and eggs.

Knock out GnRH and the whole reproductive axis goes dark. That's the central fact of reproductive endocrinology.

How does gonadorelin work?

Gonadorelin works by binding the GnRH docking site, a protein parked on pituitary cells called gonadotrophs. When gonadorelin attaches, the cell fires a calcium signal. The cell then dumps stored LH and FSH into the bloodstream.

Its plasma lifespan is just 2 to 4 minutes. This appears to be a feature rather than a limitation: a short half-life permits pulsatile administration without inter-dose accumulation — mirroring the physiological mechanism of hypothalamic GnRH release.

The rhythm rule: same molecule, opposite outcomes

Here's the part that trips people up. GnRH signaling is frequency-coded. The pituitary doesn't care about the average GnRH level. It cares about the rhythm.

Pulses every 60 to 90 minutes keep LH and FSH flowing normally. Continuous exposure, even at lower total dose, does the opposite: it numbs the pituitary and shuts LH and FSH down (Boehm et al., 2015).

You can give the same patient the same drug at the same dose and get either a working axis or a chemically castrated one. The only variable is the dosing schedule. This is the single most important fact about gonadorelin pharmacology.

Downstream effects

• LH hits Leydig cells in the testes and theca cells in the ovaries. The testes make testosterone. The ovaries make androgens that get converted to estrogen.
• FSH hits Sertoli cells in the testes and granulosa cells in the ovaries. Sertoli cells support sperm production. Granulosa cells grow ovarian follicles.
• Sustained pulsatile stimulation maintains the entire downstream axis — testosterone, estrogen, spermatogenesis, and follicular development.

Clinical history: what gonadorelin used to be

Gonadorelin has a real prescription history. The FDA approved two branded products. Both are now off the U.S. market.

• Factrel (Wyeth) was the diagnostic formulation. A single dose was administered, with LH and FSH measured at 15, 30, 45, 60, and 90 minutes. The response pattern distinguished hypothalamic from pituitary pathology. Factrel was discontinued in the U.S. around 2017.
• Lutrepulse (Ferring) was the pulsatile pump system. It delivered gonadorelin every 90 minutes through a small subcutaneous infusion pump. The FDA cleared it for inducing ovulation in women with hypothalamic amenorrhea and for triggering puberty and fertility in men with hypothalamic hypogonadism. It's also off the U.S. market.

With both branded products gone, U.S. clinical use now runs through 503A compounding pharmacies or imported product. In the EU and a few other countries, approved gonadorelin formulations are still on the market.

Veterinary gonadorelin is a separate world. It's extensively approved for syncing estrus in dairy cows and treating cystic ovaries. That market dwarfs the human one in volume.

What does the evidence actually show?

Hypothalamic hypogonadism: the strongest case

This is gonadorelin's strongest evidence base. In hypothalamic hypogonadotropic hypogonadism (HH), the hypothalamus fails to produce GnRH. Examples include Kallmann syndrome and idiopathic HH. The pituitary remains functional but lacks the upstream signal.

Clinical studies have reported that pulsatile gonadorelin delivered via subcutaneous pump restored gonadotropin secretion, normalized sex-hormone levels, and induced fertility in study participants with HH (Boehm et al., 2015). Investigators have described this approach as a physiologically direct replacement for the absent hypothalamic signal.

A 2018 study in American Journal of Men's Health tested 87 men with congenital HH. The pulsatile gonadorelin pump got sperm into the ejaculate earlier than a cyclical HCG-plus-hMG regimen (Mao et al., 2018). It's one of the few direct head-to-head comparisons against any HCG-containing protocol.

Diagnostic testing

The GnRH stimulation test uses a single gonadorelin dose to probe pituitary reserve. LH and FSH are measured at fixed intervals post-administration. The response pattern distinguishes hypothalamic from pituitary pathology.

With Factrel pulled from the market, this test is now done less often. When it's done in the U.S., it uses compounded gonadorelin from a 503A pharmacy.

Ovulation induction

The Lutrepulse pump was also used to induce ovulation in women with hypothalamic amenorrhea. That includes a subset of polycystic ovary syndrome cases where the underlying problem is hypothalamic (Christin-Maitre et al., 2013). With the pump off the U.S. market, this use case has thinned out.

Veterinary use

Gonadorelin is widely used in livestock medicine. Dairy producers use it to sync estrus and treat cystic ovaries in cows. We mention it because it's the largest commercial use of the molecule globally and gives the safety record a deeper foundation than the human trials alone.

TRT adjunct: the off-label question

Research has examined whether gonadorelin may serve as an upstream alternative to HCG in contexts where exogenous testosterone suppresses the HPG axis. Exogenous testosterone reduces intratesticular testosterone, testicular volume, and spermatogenesis by shutting down endogenous LH and FSH secretion.

HCG (human chorionic gonadotropin) is the established intervention — it mimics LH directly at the Leydig cell. Gonadorelin has been positioned as an upstream alternative: pituitary stimulation to restore endogenous LH and FSH. The biological mechanism is plausible.

However, no published head-to-head RCT has compared gonadorelin to HCG for testicular preservation in study participants on exogenous testosterone. The closest published evidence is the 2018 Mao study, conducted in study participants with congenital HH rather than testosterone-replacement populations, and comparing pulsatile gonadorelin against an HCG-plus-hMG combination rather than HCG alone.

Gonadorelin

Decapeptide 10 aa Hypothalamic origin

The same synthetic GnRH decapeptide cited across the pulsatile-pump and HH-fertility studies in this review. Identical sequence to endogenous human GnRH. Currently a Peptriva roadmap SKU — reach out via the catalog page if you’d like to register interest, or explore our other endocrine-axis references.

Explore the catalog

Gonadorelin versus leuprolide and triptorelin

The naming gets confusing fast. Gonadorelin, leuprolide, triptorelin, goserelin, buserelin, and nafarelin are all called “GnRH stimulators.” That word implies they all turn the axis on. They don't.

The difference is plasma lifespan and dosing schedule. Gonadorelin is the unmodified peptide with a 2–4 minute plasma life. Leuprolide and triptorelin are modified versions with amino-acid swaps at positions 6 and 10. Those swaps make them resistant to enzymatic breakdown.

A long plasma life means the docking site stays occupied. After an initial 1- to 2-week flare, LH and FSH crash to near-castrate levels. That's exactly what oncologists want for prostate cancer.

Leuprolide and triptorelin are the standard-of-care suppressors in:

• Prostate cancer. Shut down testosterone to slow androgen-dependent tumor growth.
• Endometriosis. Shut down estrogen to calm endometrial implants.
• Uterine fibroids. Pre-op shrinkage before surgery.
• Central precocious puberty. Stop premature puberty in children.
• Gender-affirming care. Suppress endogenous sex-hormone production.
• IVF protocols. Block endogenous LH surges so doctors can run controlled ovarian stimulation.

Same molecular target. Opposite clinical outcome. When evaluating literature that describes a compound as a “GnRH stimulator,” the dosing schedule determines whether the axis is being activated or suppressed.

Dosing regimens studied in the literature

Published studies have examined several distinct dosing contexts. Regimens varied substantially by indication, and the frequency-coded pharmacology (pulsatile vs. continuous) means that schedule differences produce qualitatively different endocrine outcomes — not merely quantitative ones.

• GnRH stimulation test (historical Factrel use): A single bolus dose administered by a clinician to probe pituitary reserve, with LH and FSH sampled at fixed intervals. This was the basis of the approved Factrel diagnostic indication.
• Pulsatile pump for HH (historical Lutrepulse use): Programmable subcutaneous infusion delivering small doses at approximately 90-minute intervals around the clock, titrated to gonadotropin and gonadal-hormone response. This regimen carries the strongest published efficacy data (Boehm et al., 2015; Mao et al., 2018).
• Off-label TRT-adjunct use: Bolus administration two to three times weekly has been described in TRT-clinic practice, but this regimen has not been evaluated in a published controlled trial for testicular preservation or compared head-to-head with HCG.
• Veterinary use: Single-dose intramuscular administration. Dose varies by species and reproductive indication.

The gap between the pulsatile pump regimen and the off-label TRT-clinic bolus schedule is pharmacologically significant. Whether infrequent bolus dosing produces hormone patterns comparable to physiological pulsatility has not been established in published research.

Handling, storage, and stability

Research-grade gonadorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials. Common formats are 5 mg and 10 mg per vial. For in-vitro research applications, standard peptide reconstitution procedures apply; consult the certificate of analysis for lot-specific purity and the supplier's handling documentation for solvent compatibility.

Stability notes

• Lyophilized vial: stable at –20°C or refrigerated for the manufacturer's stated shelf life — typically 24 months from synthesis.
• Reconstituted solution: stability of approximately 14 to 28 days refrigerated has been reported, depending on solvent choice. Consult lot-specific handling documentation.
• Avoid repeated freeze-thaw cycles. Aliquoting prior to freezing is recommended.
• Protect from light. The tyrosine and tryptophan residues are susceptible to oxidative degradation under bright-light exposure.

Gonadorelin's short plasma half-life means degradation of the research compound directly reduces the available intact peptide in any in-vitro assay. Stability is more critical here than for longer-lived analogs.

Adverse events reported in the clinical literature

Commonly reported

• Mild headache reported in the post-dose period in clinical studies.
• Mild nausea or gastrointestinal discomfort. Generally transient in study cohorts.
• Injection-site reactions. Redness, mild irritation, and occasional itching documented in Factrel and Lutrepulse clinical records.
• Flushing or warmth reported transiently in some study participants following administration.

Less commonly reported

• HPG-axis dysregulation from non-pulsatile dosing. Continuous or high-bolus exposure has been shown to paradoxically suppress gonadotropin release through receptor desensitization.
• Mood changes associated with fluctuating sex-hormone levels in study participants.
• Mild hypertension or tachycardia at the time of administration in some study participants.

Rare but serious

• Anaphylaxis. Rare but documented in the Factrel and Lutrepulse safety records.
• Pituitary apoplexy. Very rare. Reported almost exclusively in study participants with a pre-existing pituitary tumor undergoing the stimulation test.

Pharmacological interactions documented in the literature include concomitant sex steroids, long-acting GnRH analogs (leuprolide, goserelin, triptorelin), and dopamine antagonists. Co-administration with long-acting GnRH analogs is generally contraindicated due to opposing receptor-level effects.

Is gonadorelin legal?

It's a strange one. Gonadorelin has a real FDA-approval history, but no current branded product is on the U.S. market. Both Factrel and Lutrepulse are gone.

Current legitimate U.S. use runs through three channels:

• 503A compounding pharmacies. A licensed compounder can fill patient-specific prescriptions under standard 503A rules.
• Imported product. Some physicians use gonadorelin formulations approved abroad (EMA, etc.) under specific clinical circumstances.
• Research reference compound. Sold as a research-use-only chemical, labeled for lab work, not for human use.

Outside the U.S., EMA-approved gonadorelin formulations remain available in the EU. Veterinary approvals are extensive worldwide.

What about WADA and sport?

Gonadorelin falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The category covers substances that manipulate endogenous testosterone in male athletes.

Because gonadorelin's mechanism drives endogenous LH and testicular testosterone, it falls within the S2 prohibition. The restriction applies year-round, in and out of competition. Researchers and clinicians working with tested populations should consult the current WADA Prohibited List directly.

Gonadorelin

5 mg / 10 mg ≥99% pure Lyophilized

The unmodified GnRH decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. The same reference compound used across the cited pulsatile-pump fertility-induction and diagnostic literature. Currently a Peptriva roadmap addition; the catalog page lists our active SKUs and the contact channels to register interest in gonadorelin specifically.

Learn more

Frequently asked questions

What is gonadorelin?

Gonadorelin is the synthetic form of GnRH (gonadotropin-releasing hormone). It's a 10-amino-acid peptide with sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. Identical to native human GnRH. Binds the pituitary docking site and triggers LH and FSH release.

Is gonadorelin FDA-approved?

It used to be. Factrel (diagnostic use) and Lutrepulse (pulsatile fertility pump) were both FDA-approved. Both are now gone from the U.S. market. Factrel left around 2017. Today, U.S. clinical use runs through 503A compounding pharmacies or imported product. EU-approved formulations are still available abroad.

Gonadorelin vs. triptorelin vs. leuprolide. What's the difference?

Gonadorelin is the unmodified native GnRH with a 2- to 4-minute plasma life. Triptorelin and leuprolide are amino-acid-swapped analogs with much longer plasma lives. The long ones keep the docking site occupied. After a brief flare, they suppress LH and FSH. That's why they're used in prostate cancer, endometriosis, precocious puberty, gender-affirming care, and IVF. Same target. Opposite job.

What does the evidence show for the TRT-adjunct use case?

The biological rationale is mechanism-plausible: gonadorelin's upstream stimulation of LH and FSH could theoretically preserve intratesticular testosterone and spermatogenesis. However, no published head-to-head RCT has compared gonadorelin to HCG for testicular preservation in testosterone-replacement contexts. The closest study (Mao et al., 2018) was conducted in study participants with congenital HH, not in exogenous-testosterone contexts, and compared pulsatile gonadorelin against an HCG-plus-hMG combination rather than HCG alone. The bolus schedules described in off-label TRT-clinic practice also differ substantially from the pulsatile pump regimen studied in HH. The off-label use is mechanism-plausible but evidence-light.

How does gonadorelin work?

It binds the GnRH docking site on pituitary cells. The cell fires a calcium signal and releases LH and FSH into the bloodstream. LH drives testosterone in men and theca androgens in women. FSH drives sperm in men and follicles in women. The key trick is frequency coding: pulses every 90 minutes turn the axis on; constant exposure shuts it off.

What's gonadorelin's WADA status?

Gonadorelin is listed on the WADA Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The prohibition applies year-round, in and out of competition, in male athletes. Researchers and clinicians working with tested populations should consult the current WADA Prohibited List directly.

How much does gonadorelin cost?

Research-grade gonadorelin in 2026 is typically priced at $30 to $80 per 10 mg vial. As a 10-residue unmodified peptide it is one of the simpler peptides to synthesize, so per-mg pricing is lower than for long-chain or modified peptides such as tesamorelin or retatrutide. Compounding-pharmacy pricing for clinical use is higher and varies by pharmacy. Pricing substantially below $20 per 10 mg vial warrants identity and purity verification given the real synthesis cost floor. For a reference-compound sourcing overview, see our how to buy peptides online article.